Inhibition of Growth of Human Prostate Cancer Xenograft by Transfection of \( p53 \) Gene: Gene Transfer by Electroporation

Kunihisa Mikata, Hiroji Uemura, Hideki Ohuchi, Shinsuke Ohta, Yoji Nagashima, and Yoshinobu Kubota

Department of Urology, Department of Pathology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan

Abstract

To date, there is no effective therapy for hormone-independent prostate cancer. Therefore, as a new strategy for refractory cancer, gene therapy is showing increasing promise. In this study, we attempted to use a nonviral gene transfer system, in vivo electroporation, in prostate cancer cell PC-3 xenografts with the wild-type \( p53 \) (wt-\( p53 \)) gene, as gene therapy for hormone-independent prostate cancer. To evaluate this in vivo gene transfer method, the \( \beta \)-galactosidase gene was transfected into xenografts by electroporation. Then, the efficiency of transfection of exogenous \( p53 \) gene by electroporation was confirmed by reverse transcription-PCR, which indicated that \( p53 \) mRNA was present in samples from xenografts. Next, to estimate the reduction of prostate cancer xenografts by this method, we measured the size of PC-3 xenografts in nude mice after electroporation with the wt-\( p53 \) gene. The growth of tumors was markedly suppressed by wt-\( p53 \) gene transfection by electroporation compared with transfection of mutated type \( p53 \) gene (\( P = 0.0027 \)) or vector only (\( P = 0.0015 \)). Furthermore, histological specimens revealed increased apoptotic cell death in \( p53 \)-transfected tumors. These results suggest that it is possible to transfer wt-\( p53 \) into prostate cancer xenografts using electroporation and to suppress the growth of tumors; they, furthermore, suggest that this system might be used for local advanced hormone-independent prostate cancer.

Introduction

Prostate cancer is the most common malignant disease in men and the second most frequent cause of cancer death in the United States (1). Recently, in Japan, patients with prostate cancer have been increasing. To date, effective therapy for prostate cancer is possible only when the disease has been diagnosed early enough to be still localized within the prostate gland. In contrast, the survival of patients with metastatic prostate cancer remains poor. Although endocrine treatment is initially highly effective and most cases experience at least partial remission for several years, treatment failure and tumor recurrence are almost inevitable several years later (2). Once prostate cancer becomes resistant to hormone therapy, there is no effective therapy at present. Some chemotherapeutic protocols have been tried; however, they are far from effective. As a new strategy for hormone-resistant prostate cancer, gene therapy is expected to be an effective therapeutic option.

The tumor suppressor \( p53 \) gene is one of the most frequently mutated genes detected in a variety of human cancers (3). Normal function of \( p53 \) includes the regulation of two critical cellular pathways: (a) the G1 checkpoint in response to DNA damage; and (b) apoptosis induced by certain stimuli, such as radiation or chemotherapeutic agents (4, 5). Therefore, \( p53 \) appears to play a key role in maintaining the integrity of the cellular genome, and on the other hand, the inactivation of \( p53 \) function by mutations or other mechanisms occurs in the process of tumorigenesis. The \( p53 \) gene also appears to be involved in the pathogenesis of prostate cancer (6). \( p53 \) mutations are associated with metastatic prostate cancer, especially hormone-refractory cancer (7, 8). It has been demonstrated that transfection of wt-\( p53 \) into prostate cancer cell lines deficient in wt-\( p53 \) can inhibit growth and suppress tumorigenicity (9).

Gene therapy using the \( p53 \) gene has been proposed for cancers characterized by inactivation of \( p53 \) function, and successful therapy will require efficient and safe gene delivery. To date, many investigations and clinical trials using transfer of viral genes encoding wt-\( p53 \) have been performed (10–16). However, viral gene transfer at present has some problems in clinical use. For example, the strong antigenicity of adenovirus is a serious problem. Furthermore, the quality control of viral particles for in vivo administration is laborious and expensive (17).

On the other hand, as in vivo nonviral gene transfer systems, calcium phosphate, lipofection, particle bombardment, and electroporation have been developed. Electroporation of cell membranes has been developed for the purpose of achieving highly efficient in vitro gene and/or drug transfer. This method has been demonstrated to have higher efficiency of gene transfer compared with other nonviral transfer systems (18). This method was introduced into in vivo systems (18–23), and might be adapted to clinical treatment, as gene therapy.

Received 10/1/01; revised 11/30/01; accepted 12/11/01.

1 This study was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
2 To whom requests for reprints should be addressed, at Department of Urology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Phone: 81-45-787-2679; Fax: 81-45-786-5775; E-mail: hu0428@med.yokohama-cu.ac.jp.

The abbreviations used are: wt-\( p53 \), wild-type \( p53 \) (gene); mt-\( p53 \), mutated \( p53 \) (gene); CMV, cytomegalovirus; X-gal, 5-bromo-4-chloro-3-indolyl-\( \beta \)-d-galactopyranoside; TdT, terminal deoxynucleotidyltransferase; TUNEL, TdT-mediated nick end labeling.
In the present study, we evaluated the antitumor activity of p53 gene therapy in human prostate cancer xenografts using this electroporation system. Our results demonstrated that in vivo electroporation had high efficiency of gene transfer and induced inhibition of tumor growth. These results suggest that gene therapy using an electroporation system could be applicable to clinical gene therapy for human prostate cancer.

Materials and Methods

Cell Lines and Establishment of Tumors in Nude Mice.

The human prostate cancer cell line PC-3 was cultured in F12 with 10% fetal bovine serum at 37°C in 3.5% CO2. These cells were trypsinized, washed with F12, and suspended in saline solution at 1 × 107 cells/0.1 ml; a 0.1-ml cell suspension was injected into each nude mouse (BALB/c, male) s.c. in the flank area bilaterally. Formation of a tumor nodule 5 mm in diameter was observed at about 1 week after cell inoculation. Each group was given injections of pC53-SN3, pC53-SCX3 or pCMV-Neo-Bam vector after electroporation. The number of mice injected with pC53-SN3 or pC53-SCX3 or pCMV-Neo-Bam vector was 12. The number of mice injected with pC53-SCX3 was 15.

Electroporation and Plasmid Injection.

A pair of disc-shaped electrodes was used to nip the tumor nodule through the skin, and a series of eight electrical pulses with pulse length of 99 μs was delivered with a standard square wave electroporator BTX T820 (BTX, Inc., San Diego, CA; Fig. 1). To determine the optimal voltage of electroporation, we delivered various levels of voltage to the xenografts. Low voltages (50–300 V) were not effective for gene transfection by electroporation, whereas high voltages (>1.2 kV) were fatal in nude mouse. The final voltage delivered was 1.0 kV/1.0-cm diameter of xenografts. Then, we delivered an appropriate pulse length and frequency of pulses according to previous reports (20, 21). Immediately after electrical pulsing, 20 μg of plasmid DNA, wt-p53 or mt-p53 dissolved in 50 μl of Tris EDTA buffer [10 mM Tris-HCl (pH 8)-1 mM EDTA (pH 7.5)] was directly injected into the tumor nodule. Previous data indicated that uptake by electroporated cells through membrane pores is not affected by whether the molecules are present during, or are added after, the electroporating pulse (24, 25). Moreover, to avoid the problem of leakage of DNA plasmid from the needle holes, we performed electroporation before DNA plasmid injection. For wt-p53 gene transfection, we used plasmid DNA of pC53-SN3 (26), which contains wt-p53 in the sense orientation. This gene was inserted into the pCMV-Neo-Bam vector [pCMV-neo-Bam vector (6.6 kb); Ref. 26], which contains the CMV promoter. As a mt-p53, we used pC53-SCX3 (26). pC53-SN3 and pC53-SCX3 differed by a single nucleotide (Cystein to Threonine), resulting in a substitution of alanine for valine at p53 codon 143 in pC53-SCX3 (26).

This electroporation and injection were performed a total of three times at 3-day intervals. Tumor volume was measured every 3 days from the time electroporation started until the animals were killed when they exhibited signs of distress. The tumor volume was determined by measuring the largest (L) and smallest (S) diameters of the tumor and calculated as V = (L × S²)/2. The growth curve of each treatment group was plotted as the mean relative tumor volume ± SE. We continued to observe the tumor size over a period of 2 months. Because PC-3-inoculated mice became extremely exhausted or died, it was impossible to compare the tumor sizes statistically after 15 days from the first electroporation. We used dispersion analysis for statistical analysis with Fisher’s Protected Least Significance Difference as a post-hoc test.

Detection of Transgene Expression in Vivo.

To evaluate the efficiency of gene transfection by electroporation, PC-3 xenografts were subjected to electroporation three times with the β-galactosidase expression vector under the control of the human CMV gene promoter. On day 2 after electroporation, nude mice were killed. Tumors were embedded in O.C.T. compound (Miles Inc., Elkhart, IN), frozen, and sectioned on a cryostat. Frozen sections were fixed [2% (v/v) glutaraldehyde, and 2% (v/v) sodium deoxycholate, and 0.2% (v/v) NP-40, in PBS] and incubated overnight at 4°C. Each section was stained in X-gal solution for 6–8 h at room temperature and observed under a microscope.

Detection of p53 Gene Expression.

The xenografts transfected with pC53-SN3, pC53-SCX3, or pcNB vector by electroporation were removed and immediately stored at −80°C. Total RNA of these xenografts was extracted using ISOGEN (Nippon Gene Co., Tokyo, Japan) with DNase, and then converted into cDNA (cDNA) by Moloney murine leukemia virus (MMLV) reverse transcriptase. Polymerase chain reamplification of wt-p53, mt-p53, and β-actin was performed under the following conditions: denaturing for 30 s at 95°C, annealing for 30 s at 55°C, and elongation for 30 s at 72°C.
The sequences of oligonucleotides as forward or reverse primers of pc53-SN3 and \( \beta \)-actin were as follows: pc53-SN3: forward, 5'-TGACCTCCATAAGACACC-3', and reverse, 5'-AAGCGTGCTACACGGTGAAAGCTT-3'; \( \beta \)-actin: forward, 5'-TAATACGACTCACTATAGGGAGAGCGGGAGAAGTCGTGCGTGACATT-3', and reverse, 5'-GATGGAAGTGAAGGTATTTCGTG-3'. The forward primer of pc53-SN3 corresponded to the sequence of a part of the pc53 vector, which was located downstream of the transcription initiation site. The reverse primer of pc53-SN3 was a part of wt-p53.

PCR products were loaded on 2% agarose gel containing 0.5 mg/ml ethidium bromide.

**Histology and TUNEL.** The tumor tissue was fixed in 10% formalin and embedded in paraffin for histological examination. The paraffin sections were stained with H&E. To assess the incidence of apoptotic cell death, the sections were stained with an in situ cell death detection-Peroxidase kit (Boeringer Mannheim, Mannheim, Germany), according to the manufacturer's recommendations. Briefly, after deparaffinization, and dehydration and inactivation of intrinsic peroxidase activity, the sections were digested with 2 g/ml proteinase K at 37°C for 15 min. Then the sections were incubated with reaction buffer containing FITC-conjugated dUTP and TdT at 37°C for 1 h. The labeled DNAs were visualized by means of a signal converter followed by diaminobenzidine reaction. The sections were counterstained with methyl green.

**Results**

**Detection of Transgene Expression in Xenografts.** To evaluate the efficiency of gene transfer by electroporation, the \( \beta \)-galactosidase expression vector under the control of the human CMV promoter was injected after electroporation, and the xenografts were stained in X-gal solution. Transgene expression was clearly evident in the center of xenografts, showing a dark cytosol, with 25–30% of tumor cells expressing \( \beta \)-galactosidase in the sections (Fig. 2). On the other hand, expression of \( \beta \)-galactosidase was not observed in xenografts injected with the \( \beta \)-galactosidase gene without electroporation, and tumors electroporated with empty plasmid showed no color staining of X-gal (data not shown). Then, to confirm p53 transgene expression, we performed reverse transcription-PCR using total RNA extracted from xenografts. The mRNA of p53 was detected in samples from xenografts treated with pc53-SN3. Especially, p53 mRNA expression in extracts from xenografts 2 days after electroporation was detected more strongly than that after 7 days. Expression of the p53 gene gradually declined after electroporation. A similar pattern of p53 expression determined by PCR was shown in pc53-SCX3 transfection (data not shown). However, p53 mRNA was not detected in samples from xenografts treated with pCMV-Neo-Bam vector by electroporation (Fig. 3).

**Apoptosis Induced by wt-p53.** To assess the incidence of apoptotic cell death, the sections were stained with H&E or an in situ cell death detection-POD kit. The histological appearance of the xenograft was similar in the control and experimental groups, but apoptotic cells were significantly increased in the latter (data not shown). To demonstrate apoptosis, we performed TUNEL staining, which clearly revealed increased apoptotic cells in pc53-SN3-transfected PC-3 xenografts (Fig. 4a, b, and c).

**In Vivo Effect of wt-p53 Transfection by Electroporation on Tumor Growth.** To investigate the effect of wt-p53 on tumor growth, we set up three groups of BALB/c nude mice inoculated with human prostate cancer PC-3 cells. Each group was given injections of pc53-SN3, pc53-SCX3, or pCMV-Neo-Bam vector after electroporation. In each
treatment group, the tumor volume just before transfection ranged from 40 to 1666 mm$^3$ (mean, 420.1 mm$^3$). Fig. 5a shows the mean relative volume (± SE) for PC-3 xenografts treated with an injection of pC53-SN3 or pCMV-Neo-Bam vector with in vivo electroporation. Fig. 5b shows the mean relative volume (± SE) for PC-3 xenografts treated with an injection of pC53-SN3 or pC53-SCX3 with in vivo electroporation. Significant differences in the mean relative volume (± SE) between the two groups (Fig. 5, a and b) were observed from 6 days after the first electroporation. The ratio of tumor volume at 15 days to that on the 1st day in the pC53-SN3 group ranged from 1.07 to 4.01 (mean, 3.02), and the ratio in the pCMV-Neo-Bam-vector group ranged from 1.30 to 6.08 (mean, 4.13; $P = 0.0012$; Fig. 5a). The ratio of tumor volume at 15 days to that on the first day in the pC53-SN3 group ranged from 1.06 to 6.72 (mean, 3.28), and the ratio in the pC53-SNX3 group ranged from 1.65 to 18.75 (mean, 5.87; $P = 0.0027$; Fig. 5b). Accordingly, significant differences in the mean relative volume were observed between the wt-p53-transfected group and the control vector-transfected group or mt-p53-transfected group.

**Discussion**

In the present study, we attempted to use the wt-p53 gene for transfection into prostate cancer PC-3 xenograft, which is androgen-independent and has deletion of p53 protein with no function. We evaluated the antitumor growth activity of p53 gene transfer on the growth of PC-3 xenografts.

For in vivo gene transfection, many methods and techniques have been developed, and some of them have already been applied in clinical trials. In most cases, genes are transferred into tissues through the infectivity of viral particles. The retroviral system can achieve highly efficient integration, providing the potential for permanent gene expression. However, the system has some major disadvantages, such as typically a low titer, instability of the viral vector obtained, and the requirement for target cell division for integration and expression (27). Although the adenovirus system can provide more efficient gene transfer and stability of the virus, difficulties in the control of target cells and relating to readministration necessitated by the strong antigenicity of the virus are serious problems (28). Furthermore, there are some common drawbacks of viral gene transfer systems. Particularly, the quality control of viral particles for in vivo administration is laborious and expensive (17).

If an efficient and specific transfer method could be developed, the use of naked plasmid DNA might be an ideal system for gene transfer. A plasmid-mediated method would be more available and easy to handle, because the use of this system obviates the necessity to construct viral vectors, establish clones of producer cells, and assess viral titers and the presence of replication-competent helper virus, which is known to activate passive oncogenes. Also, the transfer procedure could be easily repeated because naked plasmid DNA has little antigenicity in the host body (29, 30).

Electroporation of cell membranes has been developed for the purpose of achieving highly efficient *in vitro* gene and/or drug transfer (31, 32). This system provides extremely high efficiency transfer compared with other nonviral transfer systems, including cationic liposomes and gene particle bombardment. Previously, although the application of electroporation to cultured cells has been well established, the use of *in vivo* electroporation has received little attention (18–20). However, in recent reports, an *in vivo* electroporation system was used to study the effect of cytokine gene transfection on the growth of experimental murine tumors (33, 34).

In the present study, we attempted to use electroporation with naked plasmid DNA, which is an effective gene transfer method *in vivo*. Furthermore, a wt-p53 tumor suppressor gene was used as a transfection gene, and we evaluated its antitumor activity in human prostate cancer PC-3 xenografts that contained mt-p53 alleles (9). From the results of our experiments, the efficiency of electroporation was thought to be about 25–30% of cells, determined by *β*-galactosidase expression as shown in Fig. 5. Also, it was demonstrated that the transfection of wt-p53 by electroporation could induce apoptotic cell death as shown in Fig. 5, and inhibit the growth of prostate cancer xenografts. In this study, we performed p53 gene injection and electroporation three times, and, finally, tumor growth was suppressed. With a greater number of applications, regression of tumors might become more obvious.

This report suggests that clinical application using this electroporation system for prostate cancer may be possible in the future. For example, we might be able to perform transurethral electroporation for local recurrence of prostate cancer, and also apply electroporation to the prostate or metastatic lymph nodes through laparoscopic surgery.

On the other hand, some disadvantages of this method should be considered. In our study, although transfection by electroporation inhibited the growth of PC-3 xenografts, the target area was limited to local tumors. Therefore, the growth of multiple bone metastatic lesions cannot be the target for efficient suppression. Secondly, transgene expression in the peripheral part of the xenografts was lower than that in the central region. Therefore, this procedure should be repeated several times. If the wt-p53 gene could be transfected to the peripheral part of xenografts, the suppression might be
electroporation. We also plan to use various antican-
denstrations. In a, there was a statistically
significant difference in the growth curve between pC53-SN3-transfected tumors and pCMV-NEO-BAM vector-
transfected tumors ($P = 0.0019$). In b, there was a statistically significant dif-
fERENCE between the growth curve between pC53-SN3-transfected tumors and pC53-SNX3-transfected tumors ($P = 0.0027$).

With a view to obtaining more effective gene therapy using
electroporation for prostate cancer, we plan to attempt gene
transfer with several other genes, for instance, the apoptosis
induction gene or herpes simplex virus-thymidine kinase, the
so-called suicide gene. We also plan to use various anticancer
agents in combination with gene transfection by this
electroporation.

Acknowledgments
We thank Dr. Bert Vogelstein (Johns Hopkins Oncology Center, Baltimore,
MD) for providing us with pC53-SN3, pC53-SCX3, and pCNB vectors.

References
1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer
2. Dannul, J., and Belldegrun, A. S. Development of gene therapy for
prostate cancer using a novel promoter of prostate specific antigen. Br. J.
3. Greenblatt, M. S., Benett, W. P., Hollstein, M., and Harris, C. C. Mu-
tations in the p53 tumor suppressor gene: clues to cancer etiology and
5. Hartwell, L. H., Kastan, M. D. Cell cycle control and cancer. Science
6. Kubota, Y., Shinu, T., Uemura, H., Fujinami, K., Miyamoto, H., Torigoe,
S., Dobashi, Y., Kitamura, H., Iwasaki, Y., Danenberg, K., Danenberg,
Buzzard, G. S., Moul, J. W., and Swravastata, S. Alteration of the tumor
suppressor gene p53 in high fraction of hormone refractory prostate
8. Navone, N. M., Trocoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L.,
Nichos, W. W., Von Eschebach, A. C., and Conti, C. J. p53 protein
accumulation and gene mutaion in progression of human prostate cancer.
growth of human prostate cancer cells containing mutant p53 alleles.
Thompson, T. C. In vivo gene therapy with p53 or p21 adenovirus for
11. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Cai, D. W., Owen-
Schuba, L. B., and Roth, J. A. Retroviral wt-p53 expression vector pen-
etrates human lung cancer spheroids and inhibits growth by inducing
Clayman, G. L. Growth suppression of human head and neck cancer cells
by the introduction of a wt-p53 gene via a recombinant adenovirus.


